Autoantibody response to BPI predict disease severity and outcome in cystic fibrosis

Journal of Cystic Fibrosis

Volumn 6, Issue 3, 2007, Pages 228-233

  Carlsson, Malin ^a,b   Eriksson, Leif ^c   Pressler, Tania ^d   Kornfält, Ragnhild ^b   Mared, Lena ^c   Meyer, Peter ^b   Wiik, Allan ^e   Wieslander, Jörgen ^f   Segelmark, Mårten ^b  

^a Section of Microbiology   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d Rigshospitalet   (Denmark)

^e STATENS SERUM INSTITUT   (Denmark)

^f Wieslab AB   (Sweden)

Author keywords

ANCA; Bactericidal permeability increasing protein; Cystic fibrosis; Prognosis; Pseudomonas aeruginosa

Indexed keywords

AUTOANTIBODY; BACTERICIDAL PERMEABILITY INCREASING PROTEIN;

ADOLESCENT; ADULT; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; CYSTIC FIBROSIS; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; INFANT; LUNG FUNCTION; LUNG INFECTION; LUNG TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MICROBIOLOGICAL EXAMINATION; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RESPIRATORY FAILURE;

ADOLESCENT; ADULT; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; ANTIMICROBIAL CATIONIC PEPTIDES; BIOLOGICAL MARKERS; BLOOD PROTEINS; CARRIER STATE; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; CYSTIC FIBROSIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; INFANT; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROGNOSIS; PSEUDOMONAS AERUGINOSA;

EID: 34147150127     PISSN: 15691993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcf.2006.10.005     Document Type: Article

References (27)

1. Slieker M.G., Sanders E.A., Rijkers G.T., Ruven H.J., and van der Ent C.K. Disease modifying genes in cystic fibrosis. J Cyst Fibros 4 Suppl 2 (2005) 7-13
2. Schaedel C., de Monestrol I., Hjelte L., et al. Predictors of deterioration of lung function in cystic fibrosis. Pediatr Pulmonol 33 (2002) 483-491
3. Welsh M.J., and Ramsey B.W. Research on cystic fibrosis: a journey from the Heart House. Am J Respir Crit Care Med 157 (1998) S148-S154
4. Rowe S.M., Miller S., and Sorscher E.J. Cystic fibrosis. N Engl J Med 352 (2005) 1992-2001
5. Zhao M.H., Jayne D.R., Ardiles L.G., Culley F., Hodson M.E., and Lockwood C.M. Autoantibodies against bactericidal/permeability-increasing protein in patients with cystic fibrosis. QJM 89 (1996) 259-265
6. Sediva A., Bartunkova J., Kolarova I., et al. Antineutrophil cytoplasmic autoantibodies (ANCA) in children with cystic fibrosis. J Autoimmun 11 (1998) 185-190
7. Schultz H., Csernok E., Schuster A., Schmitz T.S., Ernst M., and Gross W.L. Anti-neutrophil cytoplasmic antibodies directed against the bactericidal/permeability-increasing protein (BPI) in pediatric cystic fibrosis patients do not recognize N-terminal regions important for the anti-microbial and lipopolysaccharide-binding activity of BPI. Pediatr Allergy Immunol 11 (2000) 64-70
8. Aebi C., Theiler F., Aebischer C.C., and Schoeni M.H. Autoantibodies directed against bactericidal/permeability-increasing protein in patients with cystic fibrosis: association with microbial respiratory tract colonization. Pediatr Infect Dis J 19 (2000) 207-212
9. Carlsson M., Eriksson L., Erwander I., Wieslander J., and Segelmark M. Pseudomonas-induced lung damage in cystic fibrosis correlates to bactericidal-permeability increasing protein (BPI)-autoantibodies. Clin Exp Rheumatol 21 (2003) S95-S100
10. Dorlochter L., Carlsson M., Olafsdottir E.J., Roksund O.D., Rosendahl K., and Fluge G. Anti-neutrophil cytoplasmatic antibodies and lung disease in cystic fibrosis. J Cyst Fibros 3 (2004) 179-183
11. Elsbach P., and Weiss J. Role of the bactericidal/permeability-increasing protein in host defence. Curr Opin Immunol 10 (1998) 45-49
12. Weiss J., and Olsson I. Cellular and subcellular localization of the bactericidal/permeability-increasing protein of neutrophils. Blood 69 (1987) 652-659
13. Segelmark M., Westman K., and Wieslander J. How and why should we detect ANCA?. Clin Exp Rheumatol 18 (2000) 629-635
14. Mahadeva R., Zhao M.H., Stewart S., et al. Vasculitis and bronchiectasis in a patient with antibodies to bactericidal/permeability-increasing protein and alpha1-antitrypsin deficiency. Chest 112 (1997) 1699-1701
15. Matsuyama W., Wakimoto J., Watanabe A., et al. Bronchiectasis with myeloperoxidase antineutrophil cytoplasmic antibody and bactericidal/permeability-increasing protein antineutrophil cytoplasmic antibody. Intern Med 38 (1999) 813-816
16. Kobayashi H. Airway biofilms: implications for pathogenesis and therapy of respiratory tract infections. Treat Respir Med 4 (2005) 241-253
17. Elzouki A.N., Eriksson S., Lofberg R., Nassberger L., Wieslander J., and Lindgren S. The prevalence and clinical significance of alpha 1-antitrypsin deficiency (PiZ) and ANCA specificities (proteinase 3, BPI) in patients with ulcerative colitis. Inflamm Bowel Dis 5 (1999) 246-252
18. Schinke S., Fellermann K., Herlyn K., et al. Autoantibodies against the bactericidal/permeability-increasing protein from inflammatory bowel disease patients can impair the antibiotic activity of bactericidal/permeability-increasing protein. Inflamm Bowel Dis 10 (2004) 763-770
19. McKone E.F., Emerson S.S., Edwards K.L., and Aitken M.L. Effect of genotype on phenotype and mortality in cystic fibrosis: a retrospective cohort study. Lancet 361 (2003) 1671-1676
20. Standardization of Spirometry, 1994 Update. American Thoracic Society. Am J Respir Crit Care Med 1995; 152:1107-36.
21. Aurora P., Wade A., Whitmore P., and Whitehead B. A model for predicting life expectancy of children with cystic fibrosis. Eur Respir J 16 (2000) 1056-1060
22. Solymar L., Aronsson P.H., Bake B., and Bjure J. Nitrogen single breath test, flow-volume curves and spirometry in healthy children, 7-18 years of age. Eur J Respir Dis 61 (1980) 275-286
23. Quanjer P.H., Tammeling G.J., Cotes J.E., Pedersen O.F., Peslin R., and Yernault J.C. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl 16 (1993) 5-40
24. De Boeck K. Improving standards of clinical care in cystic fibrosis. Eur Respir J 16 (2000) 585-587
25. Höiby N. Microbiology in cystic fibrosis. In: Hodson M. (Ed) (2000), Arnold, London 83-108
26. Rasmussen N., Sjolin C., Isaksson B., Bygren P., and Wieslander J. An ELISA for the detection of anti-neutrophil cytoplasm antibodies (ANCA). J Immunol Methods 127 (1990) 139-145
27. Aaron S.D., Ramotar K., Ferris W., et al. Adult cystic fibrosis exacerbations and new strains of Pseudomonas aeruginosa. Am J Respir Crit Care Med 169 (2004) 811-815